Int J Med Sci 2022; 19(5):831-832. doi:10.7150/ijms.71659 This issue

Erratum

Estrogen receptor α/prolactin receptor bilateral crosstalk promotes bromocriptine resistance in prolactinomas: Erratum

Zhengzheng Xiao1✉, Xiaoli Yang2, Kun Zhang3, Zebin Liu1, Zheng Shao1, Chaojun Song1, Xiaobin Wang4✉, Zhengwei Li5

1. Department of Henan Key Laboratory of Cancer Epigenetics; Cancer Institute, Department of Neurosurgery, The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, Henan 471003.
2. Department of General Practice, The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, Henan 471003.
3. Spine Tumor Center, Department of Orthopedic Oncology, Changzheng Hospital, Second Military Medical University, Shanghai 210011.
4. Carson International Cancer Centre, Shenzhen University General Hospital and Shenzhen University Clinical Medical Academy Centre, Shenzhen University, Shenzhen, Guangdong 518000.
5. Department of Neurosurgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Xiao Z, Yang X, Zhang K, Liu Z, Shao Z, Song C, Wang X, Li Z. Estrogen receptor α/prolactin receptor bilateral crosstalk promotes bromocriptine resistance in prolactinomas: Erratum. Int J Med Sci 2022; 19(5):831-832. doi:10.7150/ijms.71659. Available from https://www.medsci.org/v19p0831.htm

File import instruction

Corrected-article in Int J Med Sci, Volume 17, 3174